Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
← catalyst calendarNCT06553625 · readout ≤ 3,421 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
4
Countries
Germany, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-29 | actual | When the study began enrolling |
| Primary completion | Dec 2035 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Parkinson Disease
- Dystonia
- Essential Tremor
- Movement Disorders
Intervention
- Device: Radiofrequency Ablation
Primary outcome
what the primary-completion date above is the date OFChange in patient's quality of life (QoL) during the study as compared with baseline
measured Up to 24-Months
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed